Denne sides oplysninger er på engelsk.
ADZYNMA is an enzyme replacement therapy (ERT) indicated for the treatment of ADAMTS13 deficiency in children and adult patients with congenital thrombotic thrombocytopenic purpura (cTTP). ADZYNMA can be used for all age groups.*,1
Discover how ADZYNMA works by watching this short video
COMING SOON
rADAMTS13 is a recombinant form of the endogenous ADAMTS13. ADAMTS13 is a plasma zinc metalloprotease that regulates the activity of von Willebrand factor (VWF) by cleaving large and ultra-large VWF multimers to smaller units and thereby reducing the platelet binding properties of VWF and its propensity to form microthrombi. rADAMTS13 is expected to reduce or eliminate the spontaneous formation of VWF-platelet microthrombi that leads to platelet consumption and thrombocytopenia in patients with cTTP.1
* ADZYNMA contains apadamtase alfa, a human recombinant “A disintegrin and metalloproteinase with thrombospondin motifs 13” (rADAMTS13). It is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.¹
References and acronyms
- ADZYNMA (rADAMTS13) EU Summary of Product Characteristics. August 2024.
ADAMTS13, A disintegrin and metalloproteinase with a thrombospondin motifs 13
cTTP, Congenital TTP
CHO, Chinese hamster ovary
DNA, Deoxyribonucleic acid
ERT, Enzyme replacement therapy
rADAMTS13, Recombinant ADAMTS13
SmPC, Summary of product characteristics
TTP, Thrombotic thrombocytopenic purpura
VWF, Von Willebrand factor
Har du brug for mere information?
Kontakt os på medinfoemea@takeda.com.
Oplysninger om produktresuméet kan findes her.
Birvirkninger eller uønskede hændelser skal indberettes til AE.DNK@takeda.com.